Surgical Science Sweden Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Tom Englund
Chief executive officer
SEK 1.7m
Total compensation
| CEO salary percentage | 82.94% |
| CEO tenure | 1yr |
| CEO ownership | 0.03% |
| Management average tenure | 4.7yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Surgical Science Sweden's (STO:SUS) Conservative Accounting Might Explain Soft Earnings
Aug 31
Earnings Miss: Surgical Science Sweden AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
Aug 24What You Can Learn From Surgical Science Sweden AB (publ)'s (STO:SUS) P/E After Its 32% Share Price Crash
Aug 20The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS) Even After Diving 27%
Mar 14Surgical Science Sweden's (STO:SUS) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Mar 01
Regulatory Approvals For New Robotics Entrants Will Drive Demand For Simulation Products
Strength in the Educational Products segment and rising demand for simulators indicate potential revenue growth and diversification opportunities.The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS)
Nov 12Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | SEK 92m |
| Mar 31 2025 | n/a | n/a | SEK 141m |
| Dec 31 2024 | SEK 2m | SEK 1m | SEK 132m |
Compensation vs Market: Tom's total compensation ($USD178.42K) is below average for companies of similar size in the Swedish market ($USD585.54K).
Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.
CEO
Tom Englund (49 yo)
Mr. Tom Englund serves as Director at Intelligent Ultrasound Group plc since February 18, 2025. He is Chief Executive Officer of Surgical Science Sweden AB (publ) from October 1, 2024. He joined Surgical S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1yr | SEK 1.67m | 0.032% SEK 1.5m | |
| Co-Founder & CTO | 6.8yrs | no data | no data | |
| Chief Financial Officer | 7.8yrs | no data | 0.047% SEK 2.2m | |
| Chief Operating Officer | 4.8yrs | no data | no data | |
| IR Manager | no data | no data | no data | |
| Head of Global Sales | 4.8yrs | no data | no data | |
| Chief Product & Marketing Officer | 3.9yrs | no data | 0.036% SEK 1.7m | |
| Head of Development | 5.9yrs | no data | no data | |
| Chief Innovation Officer | 4.7yrs | no data | no data | |
| Executive Vice President of International Sales & Educational Products | no data | no data | no data | |
| Chief Revenue Officer | less than a year | no data | 0.00098% SEK 45.3k | |
| Chief R&D Officer | less than a year | no data | 0.024% SEK 1.1m |
Experienced Management: SUS's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 20.8yrs | no data | no data | |
| Director | 20.8yrs | no data | 13.99% SEK 646.4m | |
| Chairman of the Board | 1.2yrs | SEK 6.12m | 0.63% SEK 29.2m | |
| Independent Director | 8.8yrs | no data | 0.0027% SEK 126.6k | |
| Independent Director | 2.4yrs | no data | 0.00069% SEK 31.9k | |
| Independent Director | 4.4yrs | no data | 0.0026% SEK 117.8k | |
| Independent Director | 4.4yrs | no data | 0.0020% SEK 90.6k |
Experienced Board: SUS's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 15:31 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surgical Science Sweden AB (publ) is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Jonsson | Berenberg |
| Viktor Högberg | Danske Bank |
| Jonatan Andersson | DNB Carnegie |